Praxis Precision Medicines, Inc. (PRAX) Sentiment Analysis

Praxis Precision Medicines, Inc. (PRAX) has an ST Score of 62.9 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on PRAX is Buy based on 18 analyst ratings. Our own ST Score grades it B (62.9/100). This is data, not investment advice — always do your own research.

Praxis Precision Medicines, Inc. (PRAX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Praxis Precision Medicines, Inc. (PRAX) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Praxis Precision Medicines, Inc. (PRAX) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Praxis Precision Medicines, Inc. (PRAX) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Praxis Precision Medicines, Inc. (PRAX) is $603.83 from 18 analysts, which is +1.0% versus the recent price of $300.65.

Praxis Precision Medicines, Inc. (PRAX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.